8-K: Alphatec Prices Upsized $350 Million Convertible Senior Notes Offering

Alphatec Holdings announces the pricing of a $350 million convertible senior notes offering due in 2030, increased from the initially planned $300 million.

Summary

• Alphatec Holdings, Inc. has priced its offering of $350 million in convertible senior notes due 2030.
• The offering was upsized from the previously announced $300 million.
• The notes are being offered in a private placement to qualified institutional buyers under Rule 144A of the Securities Act of 1933.
• The issuance is scheduled to settle on March 7, 2025, subject to customary closing conditions.
• The initial purchasers have an option to purchase an additional $55 million in notes.
• The notes will bear interest at 0.75% per annum, payable semi-annually on March 15 and September 15, starting September 15, 2025.
• The notes will mature on March 15, 2030, unless earlier repurchased, redeemed, or converted.
• Before September 17, 2029, conversion is only allowed upon certain events; after that date, holders can convert at any time until shortly before maturity.
• The initial conversion rate is 64.3407 shares per $1,000 principal amount, equivalent to approximately $15.54 per share, a 32.5% premium over the March 4, 2025 closing price of $11.73.
• The company has the option to redeem the notes for cash starting March 20, 2028, under certain conditions.
• Holders can require ATEC to repurchase the notes if a fundamental change occurs.
• ATEC entered into capped call transactions to reduce potential dilution, with an initial cap price of $23.46 per share.
• Net proceeds are estimated at $339 million, or $392.4 million if the option is fully exercised.
• Approximately $36.7 million will fund the capped call transactions, and $268.4 million will repurchase $253 million of 2026 notes.
• The remainder will be used for general corporate purposes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The upsized offering and use of proceeds to manage debt are positive signals. However, the inherent risks of convertible notes and potential dilution temper the overall outlook.

Positives

• The offering was upsized from $300 million to $350 million, indicating strong investor demand.
• The company is using a significant portion of the proceeds to repurchase existing debt, potentially improving its capital structure.
• Capped call transactions are in place to mitigate potential dilution from the conversion of the notes.
• The conversion price represents a premium of 32.5% over the recent stock price.

Negatives

• The notes are unsecured obligations, meaning they are not backed by specific assets.
• The company will incur additional expenses related to the offering, including discounts, commissions, and capped call transactions.
• The conversion of the notes could lead to dilution of existing shareholders' equity.

Risks

• Market conditions could affect the company's ability to effectively apply the net proceeds.
• The option counterparties' hedging activities could impact the market price of ATEC's common stock.
• The company's business is subject to risks described in its SEC filings.
• The company may not consummate the offering described in the press release.

Future Outlook

The company intends to use the net proceeds from the offering for capped call transactions, to repurchase existing convertible notes, and for general corporate purposes. The company may also enter into additional capped call transactions if the initial purchasers exercise their option to purchase additional notes.

Industry Context

This offering reflects a common strategy in the medical device industry to manage debt and capital structure, especially for companies with growth potential but not yet consistently profitable. Convertible notes provide a flexible financing option, allowing companies to raise capital without immediate equity dilution, while offering investors potential upside through conversion.

Comparison to Industry Standards

• Similar convertible note offerings in the medical device space often have interest rates between 0% and 2%, making ATEC's 0.75% rate relatively low, potentially reflecting investor confidence.
• Conversion premiums typically range from 25% to 40%, placing ATEC's 32.5% premium within the standard range.
• Companies like NuVasive and Globus Medical have used convertible notes to fund acquisitions and R&D, similar to ATEC's stated use of proceeds for general corporate purposes.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted.
• Noteholders will receive interest payments and have the potential for conversion into common stock.
• The company's financial flexibility may improve due to the debt refinancing.

Next Steps

• The offering is scheduled to settle on March 7, 2025, subject to customary closing conditions.
• ATEC will use the net proceeds as outlined, including funding capped call transactions and repurchasing existing notes.
• The option counterparties are expected to enter into derivative transactions and/or purchase shares of ATEC's common stock to hedge their positions.

Key Dates

Keywords

convertible notes, Alphatec Holdings, ATEC, offering, debt, financing, spine surgery, Rule 144A